TGA approves psilocybin and MDMA for use in treating depression and PTSD
Australia's medical regulator has approved the use of psychedelics to treat some mental health conditions, making the country one of the first in the world to "officially recognise MDMA and psilocybin as medicines". Key points: Authorised psychiatrists will be able to prescribe MDMA for PTSD and psilocybin for treatment-resistant depression The drugs have only been approved for use under controlled medical settings Studies have supported the use of psychedelics to treat mental health conditions, but experts have called for more data on the long-term effects International studies looking at psychedelics' ability to treat mental health conditions have shown promising results, however experts have urged caution and called for more research into their long-term effects before making them a mainstream treatment. Trials promising but experts stress more research needed There are no TGA-approved medicines containing MDMA or psilocybin available in Australia, meaning authorised psychiatrists will need to supply patients with "unapproved" medicines containing those substances. Senior lecturer at Edith Cowan University Stephen Bright said the decision made "Australia the first country in the world to officially recognise MDMA and psilocybin as medicines".
Three years after clinical trial, ketamine provides hope for severely depressed
Discover Related
Psychedelic therapy may soon be funded for veterans with PTSD, depression
Antidepressants are over-prescribed, but genuinely help some patients
Insomnia, depression treatment a click away
I stopped taking antidepressants – I should have known better
FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)
Research that shows fish responding to ketamine may hold clues for human behavior
Psychedelic Therapy Begins In Colorado, Causing Conservatives, Veterans To Clash
Psychedelic therapy begins in Colorado, causing tension between conservatives and veterans
Ketamine and governance shouldn't mix
Trial to improve antidepressant withdrawal
Vagus nerve stimulation may relieve treatment-resistant depression, study finds
Vagus nerve stimulation may relieve treatment-resistant depression, study finds
Hundreds of alerts over deaths linked to antidepressants taken by Thomas Kingston
What is Citalopram? The anti-depressant linked to Thomas Kingston’s death
A scientist’s final quest is to find new schizophrenia drugs. Will he live to see them?
'Very reductive': Experts warn against major HHS changes coming from Trump's nominee
Breakthrough headset could be used to help treat depression at home
Does Ozempic also hold the secret to a cure for depression and dementia?
A new kind of drug for schizophrenia promises fewer side effects
Is the only drug for restless leg syndrome to blame for patients' suicidal thoughts?
Data on weight loss jab link to suicidal thoughts needs ‘urgent clarification’